Breathomics and treatable traits for chronic airway diseases

Paul Brinkman, Anke-Hilse Maitland-van der Zee, Ariane H. Wagener

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

PURPOSE OF REVIEW: The long-term management goals of the inflammatory airway diseases asthma and chronic obstructive pulmonary disease (COPD) are similar and focus on symptom control and reduction of exacerbation frequency and severity. Treatable traits have recently been postulated as a management concept which complements the traditional diagnostic labels 'asthma' and 'COPD', thereby focusing on therapy targeted to a patients' individual disease-associated characteristics. Exhaled volatile organic compounds (VOCs) may be utilized as noninvasive biomarker for disease activity or manifestation in asthma and COPD. In this review, we provide an overview of the current achievements concerning exhaled breath analysis in the field of uncontrolled chronic airways diseases. RECENT FINDINGS: Monitoring of (airway) inflammation and identification of (molecular) phenotypic characteristics in asthma and COPD through exhaled VOC analysis by either mass spectrometry (MS) based or sensor-driven electronic nose technology (eNose) seems to be feasible, however pending confirmation could hamper the valorization of breathomics into clinical tests. SUMMARY: Exhaled VOC analysis and the management of asthma and COPD through the concept of pulmonary treatable traits are an interesting match. To develop exhaled breath analysis into an added value for pulmonary treatable traits, multicentre studies are required following international standards for study populations, sampling methods and analytical strategies enabling external validation.
LanguageEnglish
Pages94-100
JournalCurrent opinion in pulmonary medicine
Volume25
Issue number1
DOIs
Publication statusPublished - 2019

Cite this

Brinkman, Paul ; Zee, Anke-Hilse Maitland-van der ; Wagener, Ariane H. / Breathomics and treatable traits for chronic airway diseases. In: Current opinion in pulmonary medicine. 2019 ; Vol. 25, No. 1. pp. 94-100.
@article{fb175280ede74b6bad8ecc3854225d41,
title = "Breathomics and treatable traits for chronic airway diseases",
abstract = "PURPOSE OF REVIEW: The long-term management goals of the inflammatory airway diseases asthma and chronic obstructive pulmonary disease (COPD) are similar and focus on symptom control and reduction of exacerbation frequency and severity. Treatable traits have recently been postulated as a management concept which complements the traditional diagnostic labels 'asthma' and 'COPD', thereby focusing on therapy targeted to a patients' individual disease-associated characteristics. Exhaled volatile organic compounds (VOCs) may be utilized as noninvasive biomarker for disease activity or manifestation in asthma and COPD. In this review, we provide an overview of the current achievements concerning exhaled breath analysis in the field of uncontrolled chronic airways diseases. RECENT FINDINGS: Monitoring of (airway) inflammation and identification of (molecular) phenotypic characteristics in asthma and COPD through exhaled VOC analysis by either mass spectrometry (MS) based or sensor-driven electronic nose technology (eNose) seems to be feasible, however pending confirmation could hamper the valorization of breathomics into clinical tests. SUMMARY: Exhaled VOC analysis and the management of asthma and COPD through the concept of pulmonary treatable traits are an interesting match. To develop exhaled breath analysis into an added value for pulmonary treatable traits, multicentre studies are required following international standards for study populations, sampling methods and analytical strategies enabling external validation.",
author = "Paul Brinkman and Zee, {Anke-Hilse Maitland-van der} and Wagener, {Ariane H.}",
year = "2019",
doi = "10.1097/MCP.0000000000000534",
language = "English",
volume = "25",
pages = "94--100",
journal = "Current opinion in pulmonary medicine",
issn = "1070-5287",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Breathomics and treatable traits for chronic airway diseases. / Brinkman, Paul; Zee, Anke-Hilse Maitland-van der; Wagener, Ariane H.

In: Current opinion in pulmonary medicine, Vol. 25, No. 1, 2019, p. 94-100.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Breathomics and treatable traits for chronic airway diseases

AU - Brinkman, Paul

AU - Zee, Anke-Hilse Maitland-van der

AU - Wagener, Ariane H.

PY - 2019

Y1 - 2019

N2 - PURPOSE OF REVIEW: The long-term management goals of the inflammatory airway diseases asthma and chronic obstructive pulmonary disease (COPD) are similar and focus on symptom control and reduction of exacerbation frequency and severity. Treatable traits have recently been postulated as a management concept which complements the traditional diagnostic labels 'asthma' and 'COPD', thereby focusing on therapy targeted to a patients' individual disease-associated characteristics. Exhaled volatile organic compounds (VOCs) may be utilized as noninvasive biomarker for disease activity or manifestation in asthma and COPD. In this review, we provide an overview of the current achievements concerning exhaled breath analysis in the field of uncontrolled chronic airways diseases. RECENT FINDINGS: Monitoring of (airway) inflammation and identification of (molecular) phenotypic characteristics in asthma and COPD through exhaled VOC analysis by either mass spectrometry (MS) based or sensor-driven electronic nose technology (eNose) seems to be feasible, however pending confirmation could hamper the valorization of breathomics into clinical tests. SUMMARY: Exhaled VOC analysis and the management of asthma and COPD through the concept of pulmonary treatable traits are an interesting match. To develop exhaled breath analysis into an added value for pulmonary treatable traits, multicentre studies are required following international standards for study populations, sampling methods and analytical strategies enabling external validation.

AB - PURPOSE OF REVIEW: The long-term management goals of the inflammatory airway diseases asthma and chronic obstructive pulmonary disease (COPD) are similar and focus on symptom control and reduction of exacerbation frequency and severity. Treatable traits have recently been postulated as a management concept which complements the traditional diagnostic labels 'asthma' and 'COPD', thereby focusing on therapy targeted to a patients' individual disease-associated characteristics. Exhaled volatile organic compounds (VOCs) may be utilized as noninvasive biomarker for disease activity or manifestation in asthma and COPD. In this review, we provide an overview of the current achievements concerning exhaled breath analysis in the field of uncontrolled chronic airways diseases. RECENT FINDINGS: Monitoring of (airway) inflammation and identification of (molecular) phenotypic characteristics in asthma and COPD through exhaled VOC analysis by either mass spectrometry (MS) based or sensor-driven electronic nose technology (eNose) seems to be feasible, however pending confirmation could hamper the valorization of breathomics into clinical tests. SUMMARY: Exhaled VOC analysis and the management of asthma and COPD through the concept of pulmonary treatable traits are an interesting match. To develop exhaled breath analysis into an added value for pulmonary treatable traits, multicentre studies are required following international standards for study populations, sampling methods and analytical strategies enabling external validation.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85057561766&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30325789

U2 - 10.1097/MCP.0000000000000534

DO - 10.1097/MCP.0000000000000534

M3 - Article

VL - 25

SP - 94

EP - 100

JO - Current opinion in pulmonary medicine

T2 - Current opinion in pulmonary medicine

JF - Current opinion in pulmonary medicine

SN - 1070-5287

IS - 1

ER -